Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (Nasdaq: SLDB) has granted 9,741 restricted stock units (RSUs) to a new employee as part of their inducement compensation package. The RSUs will vest in four equal annual installments, with full vesting occurring on the fourth anniversary of the grant date. The grant was issued under the Company's 2024 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). Vesting is contingent upon the employee's continued employment with the company through each vesting date.
Solid Biosciences (Nasdaq: SLDB) ha concesso 9.741 unità azionarie limitate (RSU) a un nuovo dipendente come parte del pacchetto di compenso per l'assunzione. Le RSU matureranno in quattro rate annuali uguali, con la completa maturazione che avverrà al quarto anniversario della data di concessione. La concessione è stata emessa nell'ambito del 2024 Inducement Stock Incentive Plan della Società e rispetta la Regola di quotazione 5635(c)(4) del Nasdaq. La maturazione è subordinata alla continuazione dell'impiego del dipendente presso l'azienda fino a ciascuna data di maturazione.
Solid Biosciences (Nasdaq: SLDB) ha otorgado 9,741 unidades de acciones restringidas (RSUs) a un nuevo empleado como parte de su paquete de compensación por inducción. Las RSUs se consolidarán en cuatro cuotas anuales iguales, con la plena consolidación ocurriendo en el cuarto aniversario de la fecha de concesión. La concesión se realizó bajo el 2024 Inducement Stock Incentive Plan de la Compañía y cumple con la Regla de Cotización 5635(c)(4) de Nasdaq. La consolidación depende de que el empleado continúe trabajando en la compañía hasta cada fecha de consolidación.
Solid Biosciences (Nasdaq: SLDB)는 새로운 직원에게 9,741개의 제한 주식 단위 (RSU)를 유도 보상 패키지의 일환으로 부여했습니다. RSU는 네 차례의 동등한 연간 할부로 분할되어, 부여일로부터 4주년 되는 날에 전부 완전히 귀속됩니다. 이 부여는 회사의 2024 유도 주식 인센티브 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다. 귀속은 각 귀속일마다 직원이 회사에 지속적으로 재직하는 조건에 따릅니다.
Solid Biosciences (Nasdaq: SLDB) a accordé 9.741 unités d'actions restreintes (RSU) à un nouvel employé dans le cadre de son package de compensation d'incitation. Les RSU seront acquises en quatre versements annuels égaux, avec une acquisition complète se produisant au quatrième anniversaire de la date d'attribution. L'attribution a été effectuée dans le cadre du 2024 Inducement Stock Incentive Plan de la société et respecte la règle de cotation 5635(c)(4) de Nasdaq. L'acquisition est conditionnée à la poursuite de l'emploi de l'employé au sein de l'entreprise jusqu'à chaque date d'acquisition.
Solid Biosciences (Nasdaq: SLDB) hat 9.741 beschränkte Aktieneinheiten (RSUs) an einen neuen Mitarbeiter als Teil seines Anreizvergütungspakets gewährt. Die RSUs werden in vier gleichen jährlichen Raten fällig, wobei die vollständige Fälligkeit am vierten Jahrestag des Gewährungsdatums erfolgt. Die Gewährung wurde im Rahmen des 2024 Inducement Stock Incentive Plans des Unternehmens ausgegeben und erfüllt die Nasdaq-Börsenzulassungsregel 5635(c)(4). Die Fälligkeit ist abhängig von der fortdauernden Beschäftigung des Mitarbeiters im Unternehmen bis zu jedem Fälligkeitsdatum.
- None.
- None.
CHARLESTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 9,741 restricted stock units (“RSUs”) to one newly hired employee.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
How many RSUs did Solid Biosciences (SLDB) grant in November 2024?
What is the vesting schedule for Solid Biosciences' (SLDB) November 2024 RSU grant?
Under which plan were the November 2024 SLDB RSUs granted?
